We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris : ALVIO), ci-après « Valerio Therapeutics » ou « la Société », société de biotechnologie au stade clinique spécialisée dans le...
The first dose level, evaluating 3 patients of the VIO-01-101 trial has been cleared as per the recommendations of the Clinical Review Committee. No clinically significant adverse events or...
Cash position of €6.8 million as of December 31, 2023 Financial visibility until the end of fourth quarter of 2024 Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO...
Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereafter “Valerio Therapeutics” or the “Company”, a clinical-stage biotechnology company specializing in the...
Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) Under the liquidity contract entered into between Valerio Therapeutics and Kepler Cheuvreux, the following resources...
New identity unveiled, with the aim at developing innovative therapies against cancer R&D efforts maintained for VIO-01 (formerly OX425) and AsiDNATM Optimization of PlatONTM platform...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0004 | -0.398406374502 | 0.1004 | 0.1048 | 0.099 | 44364 | 0.10019335 | DE |
4 | -0.002 | -1.96078431373 | 0.102 | 0.1054 | 0.099 | 49969 | 0.10156184 | DE |
12 | -0.016 | -13.7931034483 | 0.116 | 0.124 | 0.099 | 77994 | 0.10730116 | DE |
26 | -0.0345 | -25.6505576208 | 0.1345 | 0.1425 | 0.09 | 90115 | 0.11477824 | DE |
52 | -0.14 | -58.3333333333 | 0.24 | 0.348 | 0.09 | 86121 | 0.17269725 | DE |
156 | -0.173 | -63.36996337 | 0.273 | 0.348 | 0.09 | 81706 | 0.17631918 | DE |
260 | -0.173 | -63.36996337 | 0.273 | 0.348 | 0.09 | 81706 | 0.17631918 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions